<?xml version='1.0' encoding='utf-8'?>
<document id="27567380"><sentence text="Appropriate risk criteria for OATP inhibition at the drug discovery stage based on the clinical relevancy between OATP inhibitors and drug-induced adverse effect." /><sentence text="DDI could be caused by the inhibition of OATP-mediated hepatic uptakes" /><sentence text=" The aim of this study is to set the risk criteria for the compounds that would cause DDI via OATP inhibition at the drug discovery stage" /><sentence text=" The IC50 values of OATP inhibitors for human OATP-mediated atorvastatin uptake were evaluated in the expression system"><entity charOffset="60-72" id="DDI-PubMed.27567380.s4.e0" text="atorvastatin" /></sentence><sentence text=" In order to set the risk criteria for OATP inhibition, the relationship was clarified between OATP inhibitory effect and severe adverse effects of OATP substrates, rhabdomyolysis, hyperbilirubinemia and jaundice" /><sentence text=" Rhabdomyolysis would be caused in the atorvastatin AUC more than 9-fold of that at a minimum therapeutic dose" /><sentence text=" The atorvastatin AUC was 6- to 9-fold increased with the OATP inhibitors of which IC50 values were ≤1 μmol/L"><entity charOffset="5-17" id="DDI-PubMed.27567380.s7.e0" text="atorvastatin" /></sentence><sentence text=" Hyperbilirubinemia and jaundice would be caused with the OATP inhibitors of which IC50 values were ≤6 μmol/L" /><sentence text=" This investigation showed that the compounds with IC50 of ≤1 μmol/L would have high risk for OATP-mediated DDI that would cause severe side effects" /><sentence text=" Before the detailed analysis based on the dosage, unbound fraction in blood and effective concentration to evaluate the clinical DDI potency, this criteria enable high throughput screening and optimize lead compounds at the drug discovery stage" /><sentence text="" /></document>